Alan K. Matsumoto
Expertise in
29
conditions

Dr. Alan K. Matsumoto

Rheumatology
2730 University Blvd W, Suite 310, 
Wheaton, MD 
Accepting New Patients
Offers Telehealth
Expertise in
29
conditions
2730 University Blvd W, Suite 310, 
Wheaton, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alan Matsumoto is a Rheumatologist in Wheaton, Maryland. Dr. Matsumoto is highly rated in 29 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Juvenile Primary Osteoporosis. Dr. Matsumoto is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Illinois College Of Med (Chi/peor/rock/chm-Urb)
Specialties
Rheumatology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Arthritis And Rheumatism Associates PC
2730 University Blvd W, Suite 310, Wheaton, MD 20902
Sunday:Closed
Monday:7:30 AM - 5:30 PM
Tuesday:7:30 AM - 5:30 PM
Wednesday:7:30 AM - 5:30 PM
Thursday:7:30 AM - 5:30 PM
Friday:Closed
Saturday:Closed

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test on Clinical Outcomes and Pharmaceutical Utilization in Patients With Rheumatoid Arthritis: A Prospective, Randomized Study
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test on Clinical Outcomes and Pharmaceutical Utilization in Patients With Rheumatoid Arthritis: A Prospective, Randomized Study
Enrollment Status: Completed
Publish Date: August 09, 2023
Intervention Type: Genetic
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Enrollment Status: Completed
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Study Phase: Phase 4
Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study
Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study
Enrollment Status: Unknown
Publish Date: May 11, 2021
Intervention Type: Biological, Other
Study Drug: Orencia
Study Phase: Phase 2
Elastography as Gouty Arthropathy Outcome (EGO), a Pilot Study.
Elastography as Gouty Arthropathy Outcome (EGO), a Pilot Study.
Enrollment Status: Completed
Publish Date: October 23, 2020
View 7 Less Clinical Trials

5 Total Publications

Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial.
Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial.
Journal: Seminars in arthritis and rheumatism
Published: July 02, 2025
Similar Doctors
Julie J. Paik
Expertise in
11
conditions
Dr. Julie J. Paik
Rheumatology
Expertise in
11
conditions
Dr. Julie J. Paik
Rheumatology

Johns Hopkins Bayview Medical Center

5501 Hopkins Bayview Circle, Floor 1, 
Baltimore, MD 
 (32.2 miles away)
443-997-1552
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Paik is a Rheumatologist in Baltimore, Maryland. Dr. Paik is highly rated in 11 conditions, according to our data. Her top areas of expertise are Dermatomyositis, Polymyositis, Myositis, and Scleroderma. Dr. Paik is currently accepting new patients.

Expertise in
15
conditions
Dr. Philip Seo
Rheumatology
Expertise in
15
conditions
Dr. Philip Seo
Rheumatology

Johns Hopkins University

5501 Hopkins Bayview Cir, 
Baltimore, MD 
 (32.2 miles away)
410-550-0545
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Philip Seo is a Rheumatologist in Baltimore, Maryland. Dr. Seo is highly rated in 15 conditions, according to our data. His top areas of expertise are Granulomatosis with Polyangiitis, Vasculitis, Microscopic Polyangiitis, Takayasu Arteritis, and Tissue Biopsy. Dr. Seo is currently accepting new patients.

Expertise in
12
conditions
Dr. Virginia D. Steen
Rheumatology | Allergy and Immunology
Expertise in
12
conditions
Dr. Virginia D. Steen
Rheumatology | Allergy and Immunology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (8.9 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Virginia Steen is a Rheumatologist and an Allergy and Immunologist in Washington, Washington, D.c.. Dr. Steen is highly rated in 12 conditions, according to our data. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Kuru, and Scleroma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matsumoto's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile